pharmaphorum

AUGUST 23, 2021

The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

DNA 98

DNA Vaccine Vaccination Genetic Engineering 98

Roots Analysis

MARCH 16, 2023

It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. It is worth noting that several companies have begun to develop mRNA-based cancer immunotherapies and vaccines for infectious diseases.

Vaccine 52

Vaccine Vaccination DNA Protein 52

The Pharma Data

NOVEMBER 30, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Vaccines Taskforce and National Institute for Health Research played pivotal roles in the rapid recruitment and enrollment of volunteers. and Australia.

Clinical Development 52

Clinical Development Vaccine Vaccination Development 52

The Pharma Data

NOVEMBER 9, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. GAITHERSBURG, Md., Glenn, M.D., and globally.”. government.

Vaccine 52

Vaccine Vaccination Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 16, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 million doses of NVX-CoV2373, Novavax’ candidate vaccine against COVID-19. About NVX-CoV2373.

Protein 52

Protein Vaccine Vaccination Immune Response 52

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% “Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines. Glenn, M.D.,

Vaccine 40

Vaccine Vaccination Trials Immune Response 40

Roots Analysis

OCTOBER 30, 2023

The next generation RNA therapeutics and RNA vaccines pipeline currently features the presence of more than 20 circular RNA therapeutics and vaccines, being developed across initial stages of drug development (discovery and preclinical). The primary target indications for tRNA therapeutics include genetic and oncological disorders.

RNA 40

RNA Vaccine Vaccination Development 40

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 That analysis also showed that the Novavax COVID-19 vaccine was 96.4

Protein 97

Protein Vaccine Vaccination Trials 97

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Encoded Therapeutics develops gene therapies for the treatment of severe genetic disorders.

Gene 262

Gene Gene Therapy Genetics DNA 262

Pharmaceutical Technology

APRIL 20, 2023

Circio aims to develop new circRNA medicines initially for cancer, then plans to expand rapidly into vaccines and gene therapy. The circVec platform is a modular genetic cassette that provides instructions for the generation of multifunctional circRNAs.

Gene Therapy 240

Gene Therapy RNA Gene Development 240

Advarra

JUNE 13, 2024

Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their use is becoming increasingly common in clinical trials. How can I protect myself from exposure? What should I do if I’m exposed?

Genetic Engineering 52

Genetic Engineering Clinical Trials Clinical Trials Engineer 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. IgG antibody responses are a useful marker of antigen exposure to diagnose immunodeficiency.

Gene Expression 130

Gene Expression Gene Genetic Engineering Antibody 130

Advarra

JANUARY 11, 2024

While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines. Personalized medicine using genetic resequencing techniques, such as cell and gene therapies, enables researchers to create more customized therapies for combatting cancer.

Vaccine 52

Vaccine Vaccination Protein Antibody 52

Cloudbyz

MARCH 6, 2024

Personalized Medicine: Biologics offer the potential for personalized treatment approaches by taking into account individual variations in genetics, immune responses, and disease characteristics. Challenges and Future Directions: Despite their immense promise, biologics are not without challenges.

Gene 99

Gene Immune Response Manufacturing Gene Therapy 99

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Gene splicing using nucleases is used to design gene therapeutics for various genetic disorders.

Gene Splicing 130

Gene Splicing Gene DNA Recombinant DNA Technology 130

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. The company's lead asset involving this technology is isaralgagene civaparvovec (ST 920).

Genetics 130

Genetics DNA Genetic Engineering Antibody 130

XTalks

OCTOBER 8, 2024

Today, it’s known that the human genome encodes over a thousand microRNAs, which play vital roles in how organisms grow, differentiate and operate, uncovering a new layer of complexity in genetic regulation. Last year’s Nobel Prize in Physiology and Medicine also went to RNA researchers.

Regulation 52

Regulation Genetics Scientist RNA 52

The Pharma Data

APRIL 18, 2022

Takeda today announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid ® Intramuscular Injection (Nuvaxovid), a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older.

Vaccine 52

Vaccine Vaccination Manufacturing Clinical Trials 52

Pharmaceutical Technology

MARCH 9, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Sanofi and F. Hoffmann-La Roche are the other key patent filers in transgenic murine models.

In-Vivo 130

In-Vivo Antibody Genetics Gene 130

The Pharma Data

MAY 31, 2022

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda ( TSE:4502/NYSE:TAK ) announced to transfer the marketing authorization in Japan for Moderna’s COVID-19 vaccine Spikevax TM (mRNA-1273) from Takeda to Moderna in Japan as of August 1, 2022. Moderna, Inc., ” Authorized Use.

Vaccine 52

Vaccine Vaccination Marketing RNA 52

XTalks

AUGUST 13, 2021

British vaccine developer, Sarah Gilbert, has been honored with a Barbie doll. Gilbert is a professor at Oxford University who helped lead the development of the Oxford/AstraZeneca COVID-19 vaccine. Chika Stacy Oriuwa is a Canadian doctor and campaigner, while Dr. Jaqueline Goes de Jesus is a Brazilian biomedical engineer.

Scientist 116

Scientist Engineer Sales Vaccine 116

The Pharma Data

JULY 29, 2021

Takeda Will Focus its Efforts on Dengue, Zika and Pandemic Vaccines. HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate. President of the Global Vaccine Business Unit, Takeda. 2 Norovirus is recognized as the leading cause of acute gastroenteritis across the age spectrum.

Vaccine 52

Vaccine Vaccination Development Clinical Trials 52

Advarra

MARCH 31, 2023

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. A key part of the IBC’s evaluation is assessing the risks posed by the engineered genetic materials.

Engineer 52

Engineer Genetics Clinical Research Research 52

XTalks

SEPTEMBER 12, 2023

The challenge lies in connecting with the audience by creating standout content, optimizing marketing efforts, leveraging social media, and mastering search engine optimization (SEO) to rise above the noise in a crowded podcasting market.

Life Science 105

Life Science Branding Clinical Trials Clinical Trials 105

Pharmaceutical Technology

AUGUST 17, 2022

These capabilities comprise cell and exosome genetic engineering for expressing therapeutic targets. In June 2020, AGC Biologics was selected by Novavax for large-scale production of an adjuvant for its Covid-19 vaccine candidate, NVX-CoV2373. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Manufacturing 130

Manufacturing Gene Therapy Genetic Engineering Gene 130

pharmaphorum

OCTOBER 12, 2022

Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. Inactive viruses often act as the viral vector, as they’re able to deliver genetic therapies efficiently.

Genome 105

Genome Genomics Medicine Development 105

XTalks

OCTOBER 21, 2020

The answer may lie in the genetic code of the virus, which scientists at Duke University have found contains several silent mutations that affect protein folding. Related: Study Dispels Claim that COVID-19-Causing Coronavirus is Lab-Engineered. So studying the genetics of the current coronavirus strain remains important.

RNA 98

RNA Protein Genomics Genome 98

The Pharma Data

MARCH 14, 2023

QDENGA is the only dengue vaccine approved in Brazil for use in individuals regardless of previous exposure to dengue and without the need for pre-vaccination testing. QDENGA is the only dengue vaccine approved in Brazil for use in individuals regardless of previous exposure to dengue and without the need for pre-vaccination testing.

Vaccine 40

Vaccine Vaccination Trials Genetics 40

Delveinsight

DECEMBER 8, 2020

As its lead program, KaliVir is developing VET2-L2 leveraging its unique technology platform based on a genetically modified vaccinia virus. VET2-L2 is an oncolytic vaccinia virus that can be delivered intravenously to cancer patients.

Licensing 52

Licensing Licensing Gene Therapy Antibody 52

XTalks

MARCH 8, 2022

From leading COVID-19 vaccine developments to being at the helm of the latest gene therapies and inventing ground-breaking DNA technologies like CRISPR, women have been at the forefront of some of the most leading-edge scientific discoveries in recent years, both as innovators and leaders.

Life Science 105

Life Science Gene Therapy DNA Vaccine 105

Advarra

AUGUST 10, 2023

Gene therapy has achieved notable successes, particularly in treating resistant or refractory B cell leukemias (achieving overall response rates around 90% or greater) and the speed with which COVID-19 vaccines were developed under the original Operation Warp Speed. Why Warp Speed for Rare Diseases?

Gene Therapy 52

Gene Therapy Development Gene Drugs 52

XTalks

NOVEMBER 30, 2023

This candidate, derived from a person’s own genetically modified cells, aims to restore the Gag-specific CD4+ T cell response in those receiving antiretroviral therapy. Promising HIV Vaccines in Clinical Trials Advancements in preventable therapeutic options for HIV are currently in progress. In November 2023, Hookipa Pharma Inc.,

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

Advarra

JULY 6, 2023

When conducting a trial involving engineered genetic materials, incidents involving occupational safety and environmental protection are also reportable to the IBC. The IBC will review the incident in a convened committee meeting to determine if any additional actions are required.

Genetics 52

Genetics Engineer Research Gene Therapy 52

XTalks

DECEMBER 13, 2023

Related: Top 30 Pharma Companies in 2023: Statistics and Trends 1) Moderna Compound annual growth rate: 415 percent Moderna, headquartered in Massachusetts, is a prominent biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines. vaccine, mRNA-1273.815.

Genetics 111

Genetics Vaccine Vaccination DNA 111

Pharmaceutical Technology

MAY 2, 2023

IO agents include the classes of immune checkpoint modulators, cell therapies, bispecific antibodies, oncolytic viruses, therapeutic vaccines, and cytokines. All currently approved CAR-Ts are autologous, with the patient’s T-cells being genetically engineered to target antigens expressed by the cancerous cells.

Genetic Engineering 130

Genetic Engineering Antibody Clinical Trials Clinical Trials 130

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. These therapeutics are broadly classified into two categories, namely coding RNAs and non-coding RNAs.

RNA 40

RNA Protein Genetics Gene Expression 40

XTalks

JUNE 18, 2024

In a field quickly gaining attention for its role in vaccine development and personalized medicine, Elixirgen Therapeutics stands out through its pursuit of innovation and safety. Founded in Baltimore, Maryland, a vibrant science hub, Elixirgen Therapeutics emerged from a vision to harness the untapped potential of mRNA technology.

Protein 52

Protein RNA Genetics Gene Expression 52